Immatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic Melanoma

Immatics N.V. announced positive results from an extended Phase 1b trial of its IMA203 PRAME cell therapy in metastatic melanoma patients, demonstrating a 56% confirmed objective response rate and durable responses lasting over 2.5 years. The cutaneous melanoma subgroup showed a 50% response rate, while uveal melanoma patients had a 67% response rate, supporting the ongoing Phase 3 SUPRAME trial evaluating IMA203 in advanced cutaneous melanoma post-checkpoint inhibitor therapy. These findings highlight IMA203's potential as a significant therapeutic option for melanoma patients with limited alternatives.

Analysis

Immatics N.V. (IMTX) has reported encouraging extended Phase 1b trial data for its IMA203 PRAME cell therapy in 33 heavily pretreated metastatic melanoma patients, demonstrating a favorable tolerability profile and significant clinical activity. The therapy achieved a confirmed overall objective response rate (cORR) of 56%, with a median duration of response (mDOR) of 12.1 months and ongoing durable responses observed for over 2.5 years. Specific subgroups showed strong performance, with cutaneous melanoma patients achieving a 50% cORR and uveal melanoma patients, including those refractory to other treatments, showing a 67% cORR. The median progression-free survival (mPFS) was 6.1 months overall, and median overall survival (mOS) was 15.9 months. These results bolster the ongoing Phase 3 SUPRAME trial, which aims to evaluate IMA203 in advanced cutaneous melanoma patients post-checkpoint inhibitor therapy, with a Biologics License Application (BLA) targeted for Q1 2027. The safety profile was favorable, with manageable cytokine release syndrome and infrequent, mild ICANS. While the data is promising, particularly for a heavily pretreated population with high unmet medical need, the generalizability to broader populations and the competitiveness of mOS and mPFS figures against existing therapies warrant consideration. The ongoing Phase 3 trial carries inherent risks, including potential failure to meet endpoints. Institutional investor activity in IMTX during Q1 2025 was mixed, with 40 firms adding shares and 59 decreasing positions; notably, T. Rowe Price Investment Management and Suvretta Capital Management significantly increased their holdings, while Paradigm Biocapital Advisors and Braidwell LP substantially reduced or exited their positions. Analyst sentiment appears positive, with Deutsche Bank issuing a "Buy" rating on May 28, 2025.

Key Decisions for Investors

• Investors should view the positive Phase 1b data for IMA203 as a significant de-risking event for Immatics' PRAME platform, particularly in melanoma, but remain cognizant of the risks associated with the upcoming Phase 3 SUPRAME trial results.
• Monitor the progress of the SUPRAME Phase 3 trial, especially the pre-specified interim data analysis anticipated after approximately 200 patient events, as this will be a key catalyst for IMTX.
• Consider the broad applicability of PRAME targeting across multiple cancer indications as a long-term value driver, balanced against the competitive landscape and the specific mOS and mPFS figures reported, while noting the mixed institutional sentiment which may suggest varying risk appetites or interpretations of the current data.
• Evaluate the company's financial position and runway to support the ongoing Phase 3 trial and potential BLA submission in Q1 2027, given the capital-intensive nature of late-stage clinical development.